28263460|t|Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution
28263460|a|Asunaprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, demonstrating efficacy in clinical studies in patients infected with HCV genotype 1 or 4, with either peginterferon / ribavirin or combinations of direct-acting antivirals. Because of preferential distribution of asunaprevir to the liver via organic anion-transporting polypeptide (OATP)- mediated transport, asunaprevir demonstrates high apparent oral clearance and very low plasma concentrations. Asunaprevir plasma concentrations are markedly increased by single-dose rifampin (an OATP inhibitor) and in subjects with moderate to severe hepatic impairment. In addition, modestly higher plasma concentrations of asunaprevir have been noted in subjects infected with HCV relative to healthy subjects and in Asian subjects relative to whites. At the marketed dose, infrequent hepatic transaminase abnormalities were poorly predicted by plasma concentrations. For a compound with these characteristics, hepatic concentrations may have provided an improved understanding of the in vivo pharmacokinetic and pharmacodynamic data to support decision making during development.
28263460	0	11	Asunaprevir	T103	UMLS:C3491974
28263460	16	38	HCV Protease Inhibitor	T103	UMLS:C4049839
28263460	57	62	Liver	T017	UMLS:C0023884
28263460	63	75	Distribution	T038	UMLS:C1378698
28263460	76	87	Asunaprevir	T103	UMLS:C3491974
28263460	94	150	inhibitor of the hepatitis C virus (HCV) NS3/4A protease	T103	UMLS:C4049839
28263460	178	194	clinical studies	T062	UMLS:C0008972
28263460	207	215	infected	T033	UMLS:C0439663
28263460	221	235	HCV genotype 1	T005	UMLS:C3532919
28263460	239	240	4	T005	UMLS:C3532922
28263460	254	267	peginterferon	T103	UMLS:C0982327
28263460	270	279	ribavirin	T103	UMLS:C0035525
28263460	283	295	combinations	T103	UMLS:C0013162
28263460	336	361	preferential distribution	T038	UMLS:C1378698
28263460	365	376	asunaprevir	T103	UMLS:C3491974
28263460	384	389	liver	T017	UMLS:C0023884
28263460	394	432	organic anion-transporting polypeptide	T103	UMLS:C0949791
28263460	434	438	OATP	T103	UMLS:C0949791
28263460	461	472	asunaprevir	T103	UMLS:C3491974
28263460	500	504	oral	T082	UMLS:C0226896
28263460	551	562	Asunaprevir	T103	UMLS:C3491974
28263460	623	631	rifampin	T103	UMLS:C0035608
28263460	636	640	OATP	T103	UMLS:C0949791
28263460	659	667	subjects	T098	UMLS:C0080105
28263460	692	710	hepatic impairment	T038	UMLS:C0948807
28263460	766	777	asunaprevir	T103	UMLS:C3491974
28263460	797	805	subjects	T098	UMLS:C0080105
28263460	806	814	infected	T033	UMLS:C0439663
28263460	820	823	HCV	T005	UMLS:C0220847
28263460	836	852	healthy subjects	T098	UMLS:C1708335
28263460	860	865	Asian	T098	UMLS:C0078988
28263460	866	874	subjects	T098	UMLS:C0080105
28263460	887	893	whites	T098	UMLS:C0080105
28263460	928	935	hepatic	T082	UMLS:C0205054
28263460	936	948	transaminase	T103	UMLS:C0002594
28263460	949	962	abnormalities	T033	UMLS:C0151625
28263460	1054	1061	hepatic	T082	UMLS:C0205054
28263460	1128	1135	in vivo	T082	UMLS:C1515655
28263460	1136	1151	pharmacokinetic	T062	UMLS:C0201734
28263460	1156	1171	pharmacodynamic	T062	UMLS:C1709518
28263460	1211	1222	development	T091	UMLS:C0872152